| The Health Sciences Authority (HSA) has given an approval for Celgosivir as a treatment for dengue to be tested on patients in Singapore. The clinical trial, titled CELADEN (Celgosivir as a Treatment AgainstDengue), launched last week as a joint effort between Singapore General Hospital and Duke-NUS Graduate Medical School . |
SABio’s founder A/Prof. Subhash Vasudevan (Duke-NUS), who researched Celgosivir since 2007 as a means to fight dengue, was one of the initiators of the trial. The drug was initially developed for other infectious diseases like HIV, and was not used to treat dengue fever until now. “We are taking an old drug and asking if there is a new use for it,” said A/Prof. Subhash Vasudevan . “There are no antiviral drugs ready to go into clinical trials against dengue at this point, except for this one”.
Pending the outcome of clinical trials, Celgosivir may become the world’s first drug to treat dengue fever. Currently, only supportive treatment is available for dengue. About 5,330 dengue cases were reported in Singapore last year, and up to 100 million people are infected annually worldwide.
More information about CELADEN clinical trial can be found at www.celaden.sg .
Pending the outcome of clinical trials, Celgosivir may become the world’s first drug to treat dengue fever. Currently, only supportive treatment is available for dengue. About 5,330 dengue cases were reported in Singapore last year, and up to 100 million people are infected annually worldwide.
More information about CELADEN clinical trial can be found at www.celaden.sg .
RSS Feed
